Category: Healthcare technology

The innovation conference “Keys to the new health system”, organized by the Institute for the Development and Integration of Health Care (IDIS Foundation), in collaboration with Farmindustria and Fenin, showed that innovation in health technology is the key to the country’s economic development and the sustainability of the health system.

In this sense, it was pointed out that stimulus plans seem to anticipate new models of public-private collaboration, collaborative environments in which the role of the health technology industry will be increasingly relevant as a dynamic agent of innovation and as a strategic ally of the system and of health professionals.

Learn more about the importance of innovation in the healthcare system and find the latest business headlines of the day with the Born2Invest mobile application.

Innovation in healthcare technology

“Covid-19 has put accessibility to the health system under control. Innovation in health technologies is a real catalyst to be able to treat more patients and is essential for the economic development of the country and the development of the health system ”, explained Maria Vila, vice president of Medtronic Spain and Portugal.

In addition, she ensured that we must invest in health technology. “We have had the news of the Inveat Plan with 800 million for the renewal of high-tech equipment, but we still have a long way to go.” He also clarified that the Inveat Plan is limited to certain equipment. “It’s not all about buying hardware, sometimes we need digital solutions,” he said.

Lluís Blanch, coordinator of the Itemas network, emphasized the contribution to innovation of the “forgotten people”, hospitals, where there is talent, money and patients. “Hospitals have already had innovation units for seven or eight years. Whether they are permeable to the entire hospital depends on who is responsible in the hospitals (managers and directors). If we get them interested in innovation, these units will continue to be there, ”he explained.

For her part, María Elena Hernando, professor at the Universidad Politécnica de Madrid (UPM), gave her point of view from the academic sphere on the work of innovation training and advocated the retention of talent. “The culture of innovation must start to come out of schools. When our students go to the hospital, they come with an open mind and are able to think of solutions. As for biomedical engineering, he stressed that its role is fundamental. “We cannot experience progress without technology helping us to diagnose and optimize time.

During this second round table moderated by Margarita Alfonsel, general secretary of Fenin, the existing barriers in the field of innovation were highlighted. The first of these is the quality of the data. “Today in hospitals there is no interoperability in the data, they do not communicate and it is really problematic. A lot of work needs to be done with industry to make data interoperable, ”said the coordinator of the Itemas network. He also identified a second obstacle: the lack of competitiveness. For this reason, he called for “more subsidies for start-ups”, because he considers it important for them to be on the territory, to take root and to be competitive.

Lluís Blanch identified two obstacles to innovation in health technologies: the lack of data interoperability and the lack of competitiveness.

The future role of health technology

For Professor UPM, the future challenge for healthcare technologies is to collect patient data in the least invasive way possible, involve the patient and achieve shared decision-making. “I expect a huge boost to this joint innovation from universities, hospitals and industry.” The speakers also underlined the importance of selling this innovation, of creating wealth and of being able to measure the return.

Ángel de Benito, Secretary General of the IDIS Foundation, closed the conference by stressing that “results in health and care depend on the degree of innovation that we are able to bring to the health system”. Finally, he assured that the engine of the new model of health care must always be a close public-private collaboration.

__

(Featured Image By EIT Going through Flickr)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or associates. Please see our disclaimer for more information.

This article may contain forward-looking statements. These forward-looking statements are generally identified by the words “believe”, “plan”, “estimate”, “become”, “plan”, “” ”and similar expressions. These forward-looking statements involve known and unknown risks and uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from forward-looking statements, which reflect the views of the management of the Company only as of the date hereof. Additionally, be sure to read these important disclosures.

First published in iSanidad, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we have made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this site. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for any losses caused by such reliance on the accuracy or reliability of the translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

The technology for this life-saving effort was devised by co-founder Keller Rinaudo, a robotics engineer from Phoenix and based in San Francisco. But the idea – and the drones – would never have seen the light of day without a lifeblood: investors motivated by the belief that they can use their capital to simultaneously generate financial returns and societal change.

Impact investors have accelerated the development of the health technology industry at a breakneck pace in recent years, thanks to the confluence of growing awareness of needs, expanding investment opportunities and growing evidence the effectiveness of impact capital.

During the pandemic, impact capital grew, as Covid-19 laid bare many healthcare challenges and raised awareness of a myriad of needs. This summer, Zipline raised some $ 250 million in capital from six investors.

“We have seen increased interest in innovations related to vaccine development, strengthening health systems globally, and improving supply chains and distribution of medical equipment,” said said Justina Lai, head of impact at Wetherby Asset Management in San Francisco. “There is also a will to fight against the disproportionate negative impact of the pandemic on low-income and vulnerable populations. ”

With some $ 715 billion in capital dedicated to impact investing, healthcare represents the third category of impact behind financial services and climate change, but it is the fastest growing area, according to a Global Impact Investing Network survey, industry study and analysis. firm in New York. In 2020, about half of impact investors said they plan to increase their stakes in healthcare impact opportunities.

Venture capital in health technologies reached $ 14 billion in 2020, nearly doubling 2019 levels of $ 7.4 billion and surpassing the previous annual record of $ 8.2 billion in 2018, according to Deloitte US, a New York-based consulting firm. This growth was not only due to a greater number of transactions, but also to a greater allocation of funds to individual transactions. Median funding per transaction last year was $ 15 million, down from the previous record of $ 10 million in 2019.

The thirst for impact capital is huge and essential to getting things done on all societal and environmental fronts, says Vikram Gandhi, Founder and CEO of New Delhi-based VSG Capital Advisors and Senior Lecturer at Harvard Business School. “There is not much there is much there is in philanthropy and government spending to solve the problems,” he says.

Americans gave some $ 470 billion to charity in 2020, while more than $ 70 trillion is in U.S. capital markets and $ 200 trillion in global markets. Impact advocates want to see a massive shift in global market capital so that impact investing picks up where charitable giving and grants end.

In healthcare, investors can play a critical role in areas where pharmaceutical companies and large corporations do not have a strong incentive to engage in research and development for anything without the potential for profit margins. high.

For healthcare entrepreneurs and innovators, as well as for investors, there is plenty of evidence that a good idea will pay off amply. In 2020, 33 innovative health technology companies raised at least $ 100 million in late stage funding, according to Deloitte. Initial public offerings and mergers and acquisitions for small health technology companies are expected to accelerate.

People seeking diversification can achieve several impact goals, including healthcare, through larger, diversified investments, explains Lai. For example, improving access to health care is inextricably linked with economic development. “Those who support poverty reduction and low-income communities recognize the importance of access to health care,” she says.

This type of larger, interconnected impact is sought by some $ 950 million of impact capital managed by Nuveen, a Chicago-based asset manager with $ 1.2 trillion under management. Assets help underserved populations with rent relief, free classes, free meals and, on the health care side, a drug delivery service.

Most of the opportunities are found in private equity and private debt, although some public options are naturally suitable for health impact goals. Municipal bonds, for example, are arguably impact investments when used to effect positive change in communities, including in their health services, facilities and technology. Investors should expect returns at least in line with general impact investments. Average returns on private capital impact debt are between 8% and 11%, and on private equity, between 16% and 18%, according to the GIIN.

Bob Sweeney, director and co-founder of the Memphis-based Global Health Impact Fund, which started three years ago, expects average annual returns of around 30% and a three to five year hold period. “We are investing in digital health, which involves the way nurses and doctors deliver care,” says Sweeney. “This is an area that is expected to grow 20% per year over the next seven years to reach half a trillion dollars.”

One of the fund’s investments is HanGenix, an Atlanta-based company that has developed ultrasound technology to ensure hospital workers adhere to handwashing procedures, which are key to reducing costs and death rates. HanGenix technology requires workers to wear a badge, which lights up when procedures, such as washing when entering a room or touching a doorknob, are not followed.

Another company in the fund’s portfolio is Plethy, a developer of technology based in San Jose, Calif., To improve post-orthopedic patient care. A Plethy sensor tracks exercise and syncs with an app that guides patients through required treatments.

While healthcare is one of the most cultivated areas of impact investing, rigorous due diligence is needed not only on finances, but also on impact, Lai says.

An investment can have positive results on one impact goal but negative results on others. “For example, while biotechnology investments, on the whole, have potential benefits through innovation in life sciences, agriculture-related biotechnology comes with potential environmental concerns such as waste biodiversity and potential ethical controversies such as testing on humans and animals, ”says Lai.

Tools for evaluating impact investments and their outcomes have evolved and will eventually provide metrics and standards to investors to help them evaluate options. According to Lai, “Impact investors should be no less rigorous in their due diligence and impact assessment in healthcare than in any other industry. ”

This article appeared in the September 2021 issue of Penta magazine

Neopharma Technologies Ltd is the owner and operator of a globally patented and award-winning drug testing device and enterprise resource management platform: TamperLoks DataVault. Today, Neopharma announced that it has been named to The Healthcare Technology Reports’ Top 100 Technology Companies for 2021 list.

“It is a true honor for our company to be recognized alongside such distinguished and respected companies as Johnson & Johnson, Boston Scientific, Abbott and 3M,” said Shaun Melville, Global Sales and Marketing Manager for Neopharma Technologies.

“Neopharma Technologies is committed to creating a global best practice workplace safety solution with its world-leading TamperLoks DataVault drug testing solution. The impact of the Covid-19 pandemic has highlighted the importance of an increase in rapid testing and how this data can be managed in real time. Neopharma Technologies has entered the market to change the way this information is securely collected, transferred, stored, managed and reported. As the company grows to increase its market share in the global drug testing industry, it seeks to better safely and securely manage data from all critical health-related IVDs, including Covid- 19, dengue fever, HIV to name a few. a few”.

Video: https://www.youtube.com/watch?v=4cdeJKUw2e8

About the Health Technology Report

The Healthcare Technology report provides market research and information, business news, updates on investment activities, and significant business developments related to the healthcare technology industry. Based in New York, the company is led by a seasoned team of editors, writers and media professionals very knowledgeable about health technology and the various companies, executives and investors that make up the industry.

About the Top 100 Healthcare Tech Companies of 2021

The Health Tech Report is pleased to announce the Top 100 Health Tech Companies of 2021. This year’s winners include a wide range of companies ranging from well-known names like Johnson & Johnson, 3M Health Care and Illumia to relatively newer but rapidly growing companies.

The diverse range of sophisticated products and services offered by these companies – from digital pharmacies to holistic patient care and from AI-powered robotics to digital healthcare payments – has not only led to the modernization of the healthcare industry. , but also to a better future where health care is democratized. for everyone.

Advances in healthcare, whether through data and communications, research and clinical trials, or consumer offerings, have also helped create an environment where more promising healthcare alternatives are possible. The pioneering companies selected for this year’s list have one thing in common: they are revolutionizing the way we live and the way we manage one of the most important factors for all of us: our health.

“Congratulations to Neopharma Technologies,” said Melissa Williams of The Healthcare Technology Report. winner 2021.

The following winners have been nominated and selected based on a thorough evaluation process. Key criteria considered included quality of product service, customer adoption, caliber of the leadership team, organizational effectiveness and business growth, among other factors.

The Top 100 Tech Companies of 2021 can be viewed here: https://thehealthcaretechnologyreport.com/

About Neopharma Technologies Ltd

Neopharma Technologies Ltd is an Australian public unlisted company. Its strategic vision is to be the world leader in early intervention in drug abuse, through reliable testing, management and rehabilitation. It is the owner and operator of a globally patented, registered and award-winning drug testing device and corporate resource management platform: TamperLoks DataVault (TLDV).

For more information visit: www.neopharmatechnologies.com

Media contact
Company Name: Neopharma Technologies Ltd
Contact: Shaun Melville, Global Sales and Marketing
E-mail: Send an email
Address:Level 4, 16 St Georges Tce
City: Perth
Country: Australia
Website: www.neopharmatechnologies.com

Loss of revenue, reduced margins and the need for greater efficiency: these are some of the fallout from the ongoing COVID-19 pandemic on the healthcare sector. This has created challenges, but also opportunities, especially in the use of technology to increase efficiency and enable clinicians to provide better care.

Ryan Hodgin, CTO of IBM Global Healthcare, and Kate Huey, Partner of IBM Healthcare, discussed some of these technological innovations during their HIMSS21 digital session, “Innovation Driven Resiliency: Redefining What’s Possible”.

The technology in question may encompass telehealth, artificial intelligence, automation, blockchain, chatbots, apps, and other things that have become mainstays of healthcare during the pandemic.

“The COVID pandemic really brought us to the brink, and we were trying to go digital very quickly,” Huey said. “It revealed gaps and holes in the system, as well as inequalities in our system, and it really sparked innovation.”

In a way, she said, science fiction is becoming scientific fact: Technologies that were once in the experimental stage are now coming to life and spurring innovation, especially quantum computing. The power of quantum computing has the potential to transform healthcare just through the sheer force of its impressive computing power.

One of the main factors accelerating technological innovation is the healthcare workforce, who have been under tremendous stress over the past 18 months, with many doctors and clinicians reporting burnout or a sense of being. outmoded. These technologies promise to reduce the burden on suppliers.

Importantly, they also promise to more actively engage healthcare consumers, who increasingly expect healthcare to be as user-friendly and experience-driven as their favorite apps or healthcare portals. online purchase.

“Sixty percent of healthcare projects fail due to lack of user acceptance,” Huey said. “We are in the age of experience and digital, because to foster digital, the experience must be experience-driven: delivering meaningful and engaging experiences that truly help consumers. And by that I mean patients, caregivers, clinicians; everybody. We need to make sure that the experience they get is seamless and easy to use, because technology has to fuel those experiences. “

At the start of the pandemic, the goal of technology was to foster resilience. According to Hodgin, the focus has been on delivering more functionality faster and real innovation – creating things like dashboards, COVID-19 trackers and risk metrics, and making them reach consumers much faster than ever before.

“It has taken the form of telehealth, chatbots, call agents, apps, and with this digital switchover we have seen a change in usage patterns, familiarity and comfort,” said Hodgin said.

Ultimately, the goal is to achieve a hybrid model of care, in which patients can access virtual and in-person channels as appropriate for their situation.

However, challenges remain, especially with the budget deficits that plague many hospitals and health systems.

“The reality is that we already had very slim operating margins in healthcare systems, and now many providers are facing budget deficits,” Huey said. “We have to look at the experiences we want to offer and see how we’re going to be more efficient. We cannot ask them to do more without giving them the necessary tools. The solutions we are putting in place must provide a better experience for them and allow them to better treat patients. “

Hodgin said that to address inequalities in care, IBM will apply what it is working on to all population groups, helping disadvantaged groups manage their care more proactively than before.

“We want the culture of innovation to really take root and not revert to the status quo,” he said.

Twitter: @JELagasse
Email the author: [email protected]

Continued Rapid Growth – Medivolve Creates Jobs for Next Generation SaaS Application Development to Improve Patient Care

TORONTO, August 10, 2021 / PRNewswire / – Medivolve inc. (“Medivolve“or the”Society“) (NEO: MEDV) (OTC: COPRF) (FRA: 4NC) has announced its intention to expand its presence by creating at least 30 new jobs over the next 18 months in its fields of design and engineering , information technology, project management and software development teams.

Currently employing 237 people across Canada and United States, this expansion will increase Medivolve’s workforce by more than 13% and help meet the increased demand for digital healthcare transformation, originally fueled by COVID-19.

“Medivolve is committed to unlocking multiple sources of revenue by providing the best telehealth services to our patients,” shares David Preiner, CEO of Medivolve. “Hiring a team of quality engineers and software developers is essential to maintain our rapid growth rate, while developing successful applications and effectively bringing them to market. “

Competition for recruitment in the technology development industry is fierce. “Medivolve examines all opportunities to identify and attract new talent. With the recruitment plans in place, we are confident that we will find world-class technical experts, who will fill a variety of hyper-specialized roles, ”said Preiner.

The majority of Medivolve’s job openings will include software engineers and developers for iOS, Android, Java and other platforms, building on the company’s current software foundation aimed at problem solving. health of millions of people.

“Growing our workforce is an integral part of our overall strategy and also provides transformational employment opportunities to fulfill our mission by not only building a motivated team that is empowered to improve patient outcomes, but also reshape the landscape of healthcare as a whole, ”concludes Preiner.

The story continues

Passionate about new technologies and improving America’s healthcare system, applicants should demonstrate excellent technical skills, strong motivation, and be prepared to take on ambitious challenges. To submit a request, visit the Medivolve website at: www.medivolve.net

About Medivolve, Inc.

Medivolve, Inc. (NEO: MEDV; OTC: COPRF; FRA: 4NC) is a healthcare technology company that seeks to reinvent the U.S. healthcare system by leveraging a bespoke telehealth platform, diagnostic network clinical and data-driven AI framework to improve patient care.

The company was born out of the health crisis; to rethink, relearn and, ultimately, reinvent a better functioning of the health system. Our network of retail collection sites play an important role in recovery by giving all Americans access to fast, accurate, and inexpensive clinical services when and where they need it. These centers will also play a central role in diagnostic tests, vaccinations and other point-of-care services. We develop disruptive technologies to make it easier and faster to identify, treat and prevent medical problems. In doing so, we strive to give patients a holistic and empowered view of their personal health.

Our long-term mission is to permanently solve systemic problems in the country’s fragmented, overly complex and costly healthcare system. Medivolve’s next phase of growth is to rotate the model and put the pieces together to create a profitable, SaaS-based healthcare technology business. We bring data-driven clinical diagnostics, physician referrals, and prescription drugs directly to people, all powered by a single, streamlined technology network. Our team is united by a powerful and singular goal: to harness the transformative power of technology to create healthier lives.
Backed by a bespoke AI-driven platform, we are developing a stealth system that constantly gets smarter, takes the guesswork out of diagnoses, and immediately reports critical health issues to deliver an unmatched level of personalization for every patient. We are committed to pushing the boundaries of what is possible, not only for our company and our shareholders, but for physicians and patients, and for the future of healthcare. We strive to achieve never-before-seen continuity of care, a game changer for our business and for the patients in the communities we serve.

Caution regarding forward-looking information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information includes, without limitation, statements regarding the hiring and engagement of engineers and software developers; or advancing revenue streams and business models for Medivolve. In general, forward-looking information can be identified by the use of forward-looking terms such as “plans”, “expects” or “does not expect”, “is planned”, “budget”, “planned”, “Estimates”, “foresees”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of these words and expressions or declares that certain actions, events or results ” could ”,“ could ”,“ could ”,“ could ”or“ will be taken ”,“ occur ”or“ be reached ”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors which may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, are significantly different from those expressed or implied. by this forward-looking information. Although the Company has attempted to identify important factors which could cause actual results to differ materially from those contained in forward-looking information, other factors may cause results not to be as anticipated, estimated or planned. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Therefore, readers should not place undue reliance on forward-looking information. The Company does not undertake to update forward-looking information, except in accordance with applicable securities laws.

NEO THE NEO EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS COMMUNICATION.

View original content to download multimedia:https://www.prnewswire.com/news-releases/healthcare-technology-company-medivolve-launches-initiative-to-hire-30-software-engineers-and-developers-301351698.html

SOURCE Medivolve Inc.

After 3 years of R&D, Hyundai Mobis, based in South Korea, has finally succeeded in developing M.Brain, a new health technology based on the measurement of brain waves.

This achievement is the subject of great attention for the application for the first time of this brainwave measurement technology to the automotive industry. Among other biosignals, measuring brain waves is known to be one of the most advanced and difficult technologies to use.

M.Brain measures the condition of the driver in real time by detecting brain waves around the ears using the headphones sensors worn. The key is the software technology that analyzes and determines the brainwave data. Hyundai Mobis has engaged in R&D and even adopted machine learning to interpret brain wave signals.

M.Brain can also be interworked with a smartphone app and warn that the driver is losing attention. Accident prevention technology also provides alerts for different sensory organs, such as sight (LED around driver’s seat), touch (vibrating seat), hearing (headrest speaker), etc.

Hyundai Mobis plans to apply various biohealth technologies to public transportation in order to contribute to public safety. Mr. Brain will first conduct an application test on public buses in Gyeonggi-do.

SEOUL – Hyundai Mobis, a parts manufacturing unit of the South Korean automotive group Hyundai, has unveiled new in-cabin healthcare technology that can measure and analyze brain waves to check the condition of drivers. The technology should prevent accidents that can occur due to drowsy driving or sudden health problems.

New healthcare technology called “Mr. Brain” will be applied to public buses for evaluation. Hyundai Mobis would extend the demonstration of its new technology to commercial vehicles. “In addition to the safety and convenience of passengers that are necessary at the stage of fully autonomous driving, we have started to deliver results in the area of ​​digital healthcare,” said Lee Seung-hwan, head of the sector. Hyundai Mobis research, in a July 21 statement.

Mr. Brain uses atrium-type sensors to detect brain waves around the ears and determine the condition of conductors. machine learning interprets what brain wave signals mean. Connected to a smartphone app, Mr. Brain sends a warning when the driver’s attention is lost. Crash Reduction Technology alerts various sensory organs using LEDs around the driver’s seat, a vibrating seat, and a headrest speaker.

Biohealth technology will eventually evolve into a personalized in-cabin security service that integrates brain waves and other biological signals to understand passenger psychology, Hyundai Mobis said, adding that at the autonomous driving stage, various services health and entertainment for passengers would emerge. regardless of the recognition of the driving environment outside the vehicle.

Hyundai Mobis has accelerated the development of sensors, cameras and other parts for autonomous vehicles and infotainment for autonomous vehicles. In 2019, the company made a strategic investment in Beijing Deep Glint Technology, a Chinese startup known for facial recognition technology, to develop motion recognition and pattern analysis using deep learning. . Facial recognition is said to be used to prevent drowsiness while driving and to detect health problems.

In March 2020, Hyundai Mobis unveiled an interior safety alert system using radar sensors to prevent child deaths from heatstroke. The radar-based Rear Occupant Alert (ROA) system alerts the driver via the dashboard or smartphone if a passenger remains in the back seat. Hyundai Mobis would upgrade its system to measure the heart rate of passengers.

Vanessa Obioha reports that Mary Akangbe, a renowned specialist practitioner in minimally invasive surgery and trained robotic assistant recently hosted the Africa Healthcare Awards and Summit in Lagos, where healthcare professionals from across Africa deliberated on technological advancements. carried out in the sector and called for more multisectoral collaboration.

Recently, Mary Akangbe, President and Founder of Zenith Global Health convened the Africa Healthcare Awards and Summit (AHAS). The two-day event that took place at the Oriental Hotel, Lagos and brought together top healthcare professionals from African countries online including South Africa, Mali, Zambia and Senegal.

For its first edition, the event looked at “advances in diabetes and cancer care” with speeches by Stanley Okolo, Director General of the West African Health Organization (WHO ) and the West African Healthcare Federation, Clare Omatseye, on the two days respectively. The two professionals underlined the importance of multisectoral collaboration within the health space.

Kebbi State First Lady Dr Zainab Shinkafi-Bagudu also spoke virtually at the event, which highlighted finances, infrastructure and resources as the main obstacles to cancer care. .

“Cancer is rapidly becoming the cause of premature death. More needs to be done to bridge the gap in cancer care between countries, economies and professions, ”she noted.

Likewise, Lagoon Hospitals CEO Dr Jimi Coker gave an overview of cancer care in Nigeria. Using statistical data, he found that there were 124,815 new cancer cases and over 78,000 deaths. Dr Mohamed El Sahili, CEO of Medland Healthcare Zambia, provided an overview of healthcare accessibility, who said that cultural biases play a role in mitigating this access to healthcare for patients.

Drug safety was a topic of discussion at the summit where one of the speakers, Dr Lolu Oju, noted that 70 percent of drugs manufactured are found outside Nigeria, with only one percent of human vaccines manufactured. This shows that the continent is lagging behind in vaccine production, especially at a time when developing countries grapple with accessibility to COVID-19 vaccines.

Akangbe is no stranger to healthcare technology. She is a practitioner specializing in minimally invasive surgery and a robotic assistant trained with an interest in AI, genomics and health technologies. As President of Zenith Global Health and Zenith Global Healthcare Professional Awards – a platform for healthcare professionals by healthcare professionals – she has been actively involved in the transformation of healthcare in Africa for over a decade.

The AHAS, she said, is an offshoot of the Zenith Global Health Awards, held in the UK for the past five years.

“We have received input from health professionals from all over Africa. In 2020 we have decided to have the African version of the Zenith Global Health Awards because we know that the impact of advances in healthcare across Africa cannot be underestimated. We have come a long way. far from where we are and healthcare professionals, organizations and stakeholders deserve recognition on the global platform. “

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Healthcare tech innovator Augnito has appointed Sahil Deswal as brand marketing director. In his new role, Deswal will be responsible for leading marketing strategy, including digital media and advertising strategy, as well as brand growth with a strong focus on global brand building.

Deswal has over a decade of experience and has been instrumental in driving the marketing and growth efforts for brands in e-commerce, media and entertainment, content, digital agencies and retailers. online services. Prior to joining Augnito, Deswal was Vice President – Marketing, Growth and Monetization at Trell. During his previous terms, he also worked with Unilodgers as vice president – global growth and marketing and as head – growth and marketing at Times Internet for the news and games business. “Augnito has done a phenomenal job transforming and supporting healthcare professionals in India, especially during times like these when healthcare is the top priority. I look forward to putting my expertise to work for the brand, ”said Deswal.

“At Augnito, we are constantly striving to make a difference with our voice technology and we are certain that with the appointment of Sahil we will be able to amplify our message and accelerate our journey to disrupt the space of the health technology in India and around the world. “said Rustom Lawyer, founder and CEO of Augnito on the appointment.

Developed in India and co-designed by doctors and AI scientists, Augnito is cloud-based text-to-speech software that guarantees error-free documentation, converting human voice to written text in real time. Augnito empowers healthcare providers by driving and scaling up electronic medical record (EMR) systems, one of the cornerstones of digital adoption in the industry. Less than a year after launch, Augnito is used by more than 5,000 physicians in 24 states. As India fights its biggest battle against Covid, Augnito has helped healthcare professionals record data effectively and efficiently.

Read also: Cannes Lions 2021: DDB Mudra wins gold in creative strategy

follow us on Twitter, Instagram, LinkedIn, Facebook